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S U M M A R Y
Vancomycin is a popular antimicrobial used to treat a variety of Gram-positive infections. Its side effect
proﬁle has been well deﬁned due to its high global utilization as a result of the emergence of
antimicrobial-resistant organisms in recent decades. Despite its widespread use, however, various
idiosyncratic reactions may occur without adequate or universal reporting. We present a case of severe
tremor due to vancomycin that has not been previously reported in the literature. Our patient might have
been prone to this adverse effect given an underlying essential tremor. Causality is presumed based on
the temporal association, while the pathophysiological link remains elusive.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Vancomycin is a commonly prescribed antimicrobial used in a
variety of infections, in particular beta-lactam-resistant Gram-
positive infections. Given its popularity and high utilization, its
side effect proﬁle has been well elucidated. However, rare
idiosyncratic reactions continue to be observed. In this report,
we present a case of severe tremor due to vancomycin therapy.
2. Case report
The case was a 69-year-old female patient treated for prosthetic
valve infective endocarditis. The patient’s past medical history
included rheumatoid arthritis, hypothyroidism, essential tremor
(as per a neurology consultation), restless legs syndrome, bicuspid
aortic valve, and ascending aorta and aortic arch aneurysm. In
February 2011 she underwent an aortic valve and hemiarch
replacement. The post-operative course was complicated by
hemorrhage and atrial ﬁbrillation, but the patient recovered well
and was discharged home in early March on spironolactone,
perindopril, metoprolol, furosemide, aspirin, lansoprazole,
levothyroxine, ropinirole, methotrexate, etanercept, prednisone,
and albuterol. Later that month, she was admitted to her local* Corresponding author. Tel.: +1 780 407 6755; fax: +1 780 407 1228.
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tazobactam and subsequently oral moxiﬂoxacin post-discharge.
Approximately 1 month later, the patient presented with fever
and tachycardia. Computed tomography scanning of the chest
revealed an extensive right-sided pulmonary embolism for which
the patient was treated with enoxaparin. A transesophageal
echocardiogram subsequently revealed a 1.4  0.9 cm mass with
a mobile component superior to the aortic valve leaﬂet and a
1.1 cm circumferential thickening of the aortic graft, consistent
with infective endocarditis and peri-graft abscess. Numerous
blood cultures performed were negative, presumably as a result of
prior/ongoing antibiotic use.
The patient was treated empirically with vancomycin
(1 g intravenous every 8 h), gentamicin (60 mg intravenous every
8 h), and rifampin (300 mg oral twice a day). Initially she tolerated
these drugs well and her fever subsided. However, 1 week into
therapy gentamicin was discontinued due to acute renal dysfunc-
tion, and ceftriaxone was added. The patient remained afebrile and
asymptomatic. Vancomycin trough levels were therapeutic
(15–20 mg/ml).
Two weeks into therapy, the patient developed an acute, severe,
whole-body tremor during infusion of vancomycin, increasing in
severity with ongoing drug administration. The tremor was high
amplitude and frequency, affecting all four limbs at rest. The
patient’s level of consciousness was unaffected and motor control
was preserved, however the tremor persisted during voluntary
movement of the extremities. The infusion was stopped and the
tremor subsided within 30 min. The severity of the tremorses. Published by Elsevier Ltd. All rights reserved.
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abated. The patient described the tremor as signiﬁcantly different
in character and considerably more severe than any symptoms of
tremor previously experienced.
Therapy with vancomycin was continued due to the uncommon
nature of the event, however the tremor recurred with the next
two infusions. Premedication with diphenhydramine and symp-
tomatic treatment with lorazepam were attempted, but no beneﬁt
was observed. On all three occasions, the tremor subsided after
discontinuation of vancomycin. Given signiﬁcant patient discom-
fort and the seemingly apparent association, vancomycin was
discontinued and substituted with daptomycin. The tremor did not
recur.
3. Discussion
Vancomycin is a glycopeptide antibiotic with broad activity
against Gram-positive bacteria. It inhibits cell wall synthesis by
binding to the D-alanyl-D-alanine portion of the cell wall – blocking
further polymerization. First discovered in 1953, it is commonly
utilized for the treatment of catheter-related infections, bacter-
emia, endocarditis, hospital-acquired pneumonia, soft tissue
infections, osteomyelitis, meningitis, and other central nervous
system infections due to Gram-positive microorganisms. Early
impure forms of vancomycin (colloquially referred to as ‘Mis-
sissippi mud’) were found to be both nephrotoxic and ototoxic,
limiting their clinical use. However, the combination of increased
tolerability due to further drug puriﬁcation and the emergence of
methicillin-resistant Staphylococcus aureus (MRSA) have resulted
in greatly increased contemporary vancomycin use.1
Common reactions due to vancomycin include ‘red man
syndrome’ (an erythematous rash on the face and upper body
with or without associated hypotension; a result of histamine
release due to rapid drug administration), eosinophilia, reversible
neutropenia, and phlebitis. Less common reactions include DRESS
syndrome (drug rash with eosinophilia and systemic symptoms),
drug fever, Stevens–Johnson syndrome, thrombocytopenia, and
vasculitis. Vancomycin-associated nephrotoxicity appears to be
dose-related, with increased incidence occurring with high trough
levels,2 or when combined with other nephrotoxic agents (e.g.,
aminoglycosides).3
Drug-induced tremor is common. Caffeine and beta-adrenergic
agonists are well recognized as both causing and exacerbating
tremors. Less commonly implicated drugs include selective
serotonin reuptake inhibitors and tricyclic antidepressants.
Drug-induced tremor is usually symmetric. Diagnosis requires
the exclusion of other medical causes of tremor, a temporal
relation to the start of therapy, a dose-dependent response, and a
lack of tremor progression. The Naranjo scale can also be used to
aid in the diagnosis of drug-induced reactions by assessing the
probability of cause and effect.4
A comprehensive search of the following key electronic
biomedical databases from inception to September 1, 2011 was
performed: Medline, Embase, Database of Abstracts of Reviews of
Effects, Health Technology Assessment, PubMed, Web of Science,
and Google Scholar. Tremor has not been previously reported as an
adverse reaction to vancomycin administration in these databases.
One case of tremor was reported in an open efﬁcacy and safetystudy of teicoplanin – a related glycopeptide.5 Although the tremor
was described as mild, therapy was discontinued.
A subsequent search of the Health Canada adverse events
database (Canada Vigilance Summary of Reported Adverse
Reactions) searched September 1, 2011, yielded six cases of
tremor potentially related to vancomycin therapy. The Summary is
a spontaneous voluntary reporting system aimed at detecting
signals of potential health product safety issues during the post-
market period. Of the six cases identiﬁed, the median patient age
was 73 years, 67% were female, 33% were documented as serious
reactions, and all but one case suspected vancomycin as the sole
drug responsible for the adverse event. Associated symptoms
included chills, pyrexia, rash, ﬂushing, vomiting, dizziness, and
abdominal pain. Doses ranged from 0.5 to 2 g every 6–24 h, and the
duration of therapy ranged from 1 to 14 days. Data on prevalence of
renal dysfunction/failure and trough levels were not available.
A similar search of the Federal Drug Administration (FDA)
Adverse Drug Events Database (AERS/Medwatch) from 1997 to
2011 yielded a total of 34 reports of tremor in which vancomycin
was the primary suspect drug. Thirty-one (91%) cases were in
adults, of which 26 (76%) were male. The highest incidence (26%)
was observed in those aged 80–89 years. Seventeen (50%) patients
required hospitalization, and ﬁve (15%) cases were considered to
be life-threatening. The most common associated symptoms
included chills, pyrexia, dyspnea, and rigors.
Though no clear evidence or pharmacological explanation can
be put forward to explain this adverse event, the temporal and
dose-dependent relationship, as well as reproducibility, support
vancomycin causality in this case. Using the Naranjo scale, this case
scores 7 out of a potential 13 points, which is considered to be a
probable association. It is surprising, given our ﬁndings, that
reports of this reaction have not been previously published, nor is
this reaction listed in any common drug information databases
(such as Lexi-Comp or Micromedex).
In summary, we report a case of severe tremor due to
vancomycin that has not been previously described in the
literature. Our patient might have been prone to this given her
underlying diagnosis of essential tremor. Causality is presumed
based on the temporal association, given the acute onset of
symptoms with vancomycin infusion and abrupt cessation with
drug discontinuation. The pathophysiological link remains elusive.
With awareness of our case and ongoing reporting perhaps the
epidemiology of this reaction can be further described and its
pathophysiology further elucidated.
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